Regeneron Pharmaceuticals (NASDAQ:REGN) Director Arthur Ryan Sells 100 Shares

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Director Arthur Ryan sold 100 shares of the firm’s stock in a transaction dated Friday, May 1st. The stock was sold at an average price of $705.24, for a total value of $70,524.00. Following the completion of the transaction, the director directly owned 17,503 shares in the company, valued at $12,343,815.72. The trade was a 0.57% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Regeneron Pharmaceuticals Stock Performance

NASDAQ:REGN traded up $7.79 on Monday, hitting $709.21. The stock had a trading volume of 554,077 shares, compared to its average volume of 748,440. The business’s 50-day simple moving average is $756.81 and its two-hundred day simple moving average is $737.56. The company has a quick ratio of 2.96, a current ratio of 3.57 and a debt-to-equity ratio of 0.06. Regeneron Pharmaceuticals, Inc. has a 52-week low of $476.49 and a 52-week high of $821.11. The stock has a market cap of $74.98 billion, a price-to-earnings ratio of 17.28, a price-to-earnings-growth ratio of 1.60 and a beta of 0.30.

Regeneron Pharmaceuticals (NASDAQ:REGN) last posted its quarterly earnings data on Wednesday, April 29th. The biopharmaceutical company reported $9.47 EPS for the quarter, topping the consensus estimate of $8.91 by $0.56. Regeneron Pharmaceuticals had a return on equity of 13.16% and a net margin of 29.65%.The firm had revenue of $3.61 billion for the quarter, compared to the consensus estimate of $3.48 billion. During the same quarter last year, the company earned $8.22 earnings per share. The business’s revenue for the quarter was up 19.0% compared to the same quarter last year. As a group, research analysts predict that Regeneron Pharmaceuticals, Inc. will post 36.05 earnings per share for the current year.

Regeneron Pharmaceuticals Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Thursday, June 4th. Investors of record on Wednesday, May 20th will be paid a dividend of $0.94 per share. This represents a $3.76 annualized dividend and a yield of 0.5%. The ex-dividend date of this dividend is Wednesday, May 20th. Regeneron Pharmaceuticals’s dividend payout ratio (DPR) is 9.16%.

Institutional Trading of Regeneron Pharmaceuticals

Several institutional investors have recently bought and sold shares of the business. Insigneo Advisory Services LLC grew its holdings in Regeneron Pharmaceuticals by 3.0% in the fourth quarter. Insigneo Advisory Services LLC now owns 445 shares of the biopharmaceutical company’s stock valued at $343,000 after purchasing an additional 13 shares during the period. Guardian Wealth Advisors LLC NC grew its holdings in Regeneron Pharmaceuticals by 3.3% in the fourth quarter. Guardian Wealth Advisors LLC NC now owns 443 shares of the biopharmaceutical company’s stock valued at $342,000 after purchasing an additional 14 shares during the period. TD Private Client Wealth LLC grew its holdings in Regeneron Pharmaceuticals by 9.7% in the fourth quarter. TD Private Client Wealth LLC now owns 169 shares of the biopharmaceutical company’s stock valued at $130,000 after purchasing an additional 15 shares during the period. MCF Advisors LLC grew its holdings in Regeneron Pharmaceuticals by 50.0% in the fourth quarter. MCF Advisors LLC now owns 45 shares of the biopharmaceutical company’s stock valued at $35,000 after purchasing an additional 15 shares during the period. Finally, Boyd Watterson Asset Management LLC OH grew its holdings in Regeneron Pharmaceuticals by 1.4% in the first quarter. Boyd Watterson Asset Management LLC OH now owns 1,087 shares of the biopharmaceutical company’s stock valued at $840,000 after purchasing an additional 15 shares during the period. 83.31% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of analysts have issued reports on REGN shares. Truist Financial reduced their price objective on Regeneron Pharmaceuticals from $801.00 to $796.00 and set a “buy” rating on the stock in a research note on Thursday. JPMorgan Chase & Co. boosted their price objective on Regeneron Pharmaceuticals from $850.00 to $950.00 and gave the company an “overweight” rating in a report on Monday, February 2nd. Royal Bank Of Canada lowered their target price on Regeneron Pharmaceuticals from $779.00 to $762.00 and set a “sector perform” rating for the company in a report on Thursday. Barclays decreased their price objective on Regeneron Pharmaceuticals from $923.00 to $917.00 and set an “overweight” rating for the company in a research note on Thursday. Finally, Cantor Fitzgerald restated an “overweight” rating and set a $800.00 price objective on shares of Regeneron Pharmaceuticals in a research note on Thursday, April 23rd. Two investment analysts have rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating and eight have given a Hold rating to the company. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $826.59.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.

Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.